Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
MAYNF MAYNE PHARMA GROUP LIMITED
0.154
+0.014+10.00%
YOY
Do not show
Hide blank lines
(FY)2022/06/30(FY)2021/06/30(FY)2020/06/30(FY)2019/06/30
Total revenue
5.89% 423.92M -12.33% 400.32M -12.86% 456.6M -0.98% 523.96M
Operating revenue
5.89% 423.92M -12.33% 400.32M -12.86% 456.6M -0.98% 523.96M
Cost of revenue
23.44% 253.77M -11.19% 205.58M 3.99% 231.49M -16.40% 222.6M
Gross profit
-12.63% 170.15M -13.49% 194.74M -25.30% 225.11M 14.64% 301.36M
Operating expense
-1.01% 171.69M -23.46% 173.44M -18.76% 226.61M 23.89% 278.92M
Selling and administrative expenses
-12.04% 75.95M -26.39% 86.34M -26.05% 117.29M 17.39% 158.62M
-Selling and marketing expense
84.09% 104.6M -23.43% 56.82M -3.21% 74.2M 25.74% 76.67M
-General and administrative expense
-197.04% -28.65M -31.48% 29.52M -47.42% 43.09M 10.53% 81.95M
Research and development costs
-22.47% 14.66M -23.60% 18.91M -4.08% 24.75M 109.75% 25.81M
Depreciation amortization depletion
18.91% 81.08M -19.36% 68.19M -10.51% 84.56M 21.61% 94.5M
-Depreciation and amortization
18.91% 81.08M -19.36% 68.19M -10.51% 84.56M 21.61% 94.5M
Operating profit
-107.25% -1.55M 1,528.71% 21.3M -106.64% -1.49M -40.56% 22.44M
Net non-operating interest income expense
0.51% -31.97M -4.48% -32.13M -86.35% -30.75M 3.69% -16.5M
Non-operating interest income
-32.90% 461K -12.82% 687K -22.44% 788K 807.14% 1.02M
Non-operating interest expense
-0.77% 32.1M 4.15% 32.35M 78.04% 31.06M 1.14% 17.44M
Total other finance cost
-30.02% 331K -2.47% 473K 546.67% 485K -- 75K
Other net income (expense)
19.31% -204.2M -128.77% -253.06M 69.24% -110.62M -91.97% -359.66M
Special income (charges)
17.50% -197.04M -122.53% -238.82M 69.49% -107.32M -84.91% -351.72M
-Less:Restructuring and merger&acquisition
-47.22% 5.01M 13.98% 9.5M -- 8.34M -- --
-Less:Impairment of capital assets
-16.26% 192.02M 131.67% 229.32M -71.86% 98.99M 90.76% 351.72M
Other non- operating income (expenses)
49.65% -7.17M -331.76% -14.24M 58.48% -3.3M -377.72% -7.94M
Income before tax
17.46% -217.82M -94.94% -263.89M 61.73% -135.37M -112.08% -353.72M
Income tax
202.42% 56.13M -34.22% -54.81M 41.64% -40.83M -115.08% -69.97M
Net income
-31.03% -273.95M -121.17% -209.08M 66.68% -94.54M -111.35% -283.75M
Net income continuous Operations
-31.03% -273.95M -121.17% -209.08M 66.68% -94.54M -111.35% -283.75M
Minority interest income
-1,509.56% -10.61M 62.26% -659K 39.48% -1.75M -956.78% -2.89M
Net income attributable to the parent company
-26.35% -263.34M -124.62% -208.42M 66.96% -92.79M -109.63% -280.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-26.35% -263.34M -124.62% -208.42M 66.96% -92.79M -109.63% -280.87M
Basic earnings per share
-20.66% -0.16 -118.45% -0.1326 68.12% -0.0607 -107.86% -0.1904
Diluted earnings per share
-20.66% -0.16 -118.45% -0.1326 68.12% -0.0607 -107.86% -0.1904
Dividend per share
Currency Unit
AUDAUDAUDAUD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment is involved in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty Products segment includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment manufactures and sells branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.
CEO: Mr. Shawn Patrick O’Brien
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist